Gland Pharma Q3 net declines 15% to Rs 232 cr due to production delays

The company had posted a consolidated net profit of Rs 273.03 crore in the same period last fiscal, Gland Pharma said in a regulatory filing

Gland Pharma
Total expenses in the third quarter were lower at Rs 688.95 crore as compared to Rs 743.43 crore in the same period a year ago
Press Trust of India New Delhi
2 min read Last Updated : Jan 23 2023 | 8:13 PM IST

Gland Pharma Ltd on Monday reported a 15 per cent decline in consolidated net profit at Rs 231.95 crore for the third quarter ended December 2022, impacted by production delays due to supply disruptions.

The company had posted a consolidated net profit of Rs 273.03 crore in the same period last fiscal, Gland Pharma said in a regulatory filing.

Consolidated revenue from operations during the quarter under review stood at Rs 938.29 crore as against Rs 1,063.33 crore in the year-ago period.

Total expenses in the third quarter were lower at Rs 688.95 crore as compared to Rs 743.43 crore in the same period a year ago.

"Challenging business environment, ongoing supply chain disruptions leading to production delays continue to impact our performance," Gland Pharma Managing Director and CEO Srinivas Sadu said.

The company's core markets US, Europe, Canada, Australia, and New Zealand accounted for 70 per cent of revenue during the quarter, maintaining a similar level of revenue contribution as compared to Q3 FY22, Gland Pharma said.

Rest of the world markets contributed 21 per cent while the India market accounted for 9 per cent of Q3 FY23 revenue and witnessed sequential recovery of business due to normalisation of insulin production line, it added.

During the quarter, total R&D expense stood at Rs 51.2 crore, at 5.5 per cent of revenue, the company said, adding the total capex incurred during the quarter was Rs 42.7 crore.

On the outlook, Sadu said the proposed acquisition of Cenexi, the company's first acquisition overseas, will enable Gland to increase its presence and expand its product and service offering capability in Europe.

"Our new production lines in our sterile facility, in Pashamylaram, will support our product portfolio of complex and differentiated delivery formats," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Gland PharmaQ3 results

First Published: Jan 23 2023 | 8:13 PM IST

Next Story